Table 2.
Company | Therapeutic | Phase I | Approval |
---|---|---|---|
Roche/Genentech | Vemurafenib (Zelboraf™) | November 2006 | August 2011 |
Pfizer | Crizotinib (Xalkori®) | December 2007 | August 2011 |
GSK | Trametinib (Mekinist™) | May 2008 | May 2013 |
Roche/Genentech | Ado-trastuzumab emtansine (Kadcyla®) | June 2009 | February 2013 |
GSK | Dabrafenib (Tafinlar®) | April 2009 | May 2013 |